#United States #Cambridge #cancer therapy #oncology #Nuvalent

Nuvalent's Participation in UBS 2025 Virtual Oncology Day

On October 1, 2025, Nuvalent, Inc., a pioneering clinical-stage biopharmaceutical firm, will partake in the UBS 2025 Virtual Oncology Day. The event is set for 3:30 PM ET, featuring insights from key executives including CEO James Porter, Ph.D., and CFO Alexandra Balcom.

Nuvalent specializes in developing targeted treatments tailored for clinically validated kinase targets in cancer. Their mission is crystal clear: to address the limitations often seen in existing cancer therapies. This focus not only aims to enhance patient outcomes but also to push the industry towards innovative solutions that combat the complexities of cancer.

The live discussion will be accessible via a webcast available in the Investor Relations area on Nuvalent's official website, www.nuvalent.com, and will remain available for approximately 30 days post-event. This presents a valuable opportunity for investors and stakeholders to understand Nuvalent’s strategic vision and technology advancements.

The company's commitment is noteworthy. Utilizing advanced expertise in chemistry and structure-based drug design, they are crafting small molecules designed to tackle drug resistance, minimize side effects, and address some of the toughest challenges in treating brain metastases. Their pipeline includes investigational candidates targeting ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with various discovery-stage research initiatives, positioning Nuvalent in a leadership role within the biopharmaceutical community.

As oncology continues to evolve, the participation of organizations like Nuvalent at significant forums, such as the UBS 2025 Virtual Oncology Day, emphasizes the critical dialogue necessary for advancement in cancer treatment. The expertise shared during these interactions is invaluable, not just for investors, but for the entire cancer treatment ecosystem. Stakeholders are encouraged to tune into this pivotal event to glean insights into Nuvalent's trailblazing approach in oncology therapy development. Through continued engagement and innovation, Nuvalent aims to redefine the treatment landscape for cancer patients around the globe.

This event stands as a testament to their relentless pursuit of scientific excellence and contributions towards developing more effective therapies for individuals diagnosed with cancer.